Clinical Trials
AOP 208
AOP 208 targets a receptor on cancer stem cells which has not been in the center of attention in cancer therapy so far, making it a first-in-class investigational drug in oncology. This pathway may have a role in several types of leukemia but importantly also various solid tumors including breast and lung cancer.
Study title AOP 208 (Serotonin Receptor 1B antagonist)
Indication Solid tumors and Acute Myeloid Leukemia and Myelodysplastic Syndrome
Eudrac / NCT No 2023-509532-25-00
Phase I, The tolerance and safety of the drug are tested in a phase-I study. Those conducting the study investigate how the active substance is absorbed by the body and draw preliminary conclusions about the appropriate dosage. The trial is conducted in a small group of healthy probands or severely ill patients.
Ropeginterferon alfa-2b
Study title ROP-ET trial, multicenter study to evaluate the efficacy and safety of Ropeginterferon alfa-2b in essential thrombocythemia patients
Indication Essential Thrombocythemia
Eudrac / NCT No EudraCT No. 2021-006888-23
Phase III, multicentre, single arm, open label
The objective of the study BESREMi®-PASS study is to gain additional information on the safety and tolerability of Ropeginterferon alfa-2b in patients with Polycythemia Vera treated with Ropeginterferon alfa-2b in routine post-authorisation use.
Study title Post-authorisation Safety Study of Ropeginterferon alfa-2b in Polycythemia Vera Patients
Indication Polycythemia Vera
Eudrac / NCT No EUPAS29462
Phase IV, multicentre, prospective, non-interventional study, observational, post-authorisation safety
Treprostinil
Study title Triple TRE, Randomized trial comparing efficacy and safety of initial triple therapy including parenteral Treprostinil to initial double oral therapy in PAH group I patients
Indication Pulmonary Arterial Hypertension
Eudrac / NCT No EU CT No: 2023-504351-26-00
Phase IV, multicentre, prospective, randomised, open label
Study name TREPaed, open-label, single-arm, non-controlled trial to evaluate the safety and tolerability of Treprostinil sodium in children below the age of 18 years with pulmonary arterial hypertension (PAH)
Indication Pulmonary Arterial Hypertension
Eudrac / NCT No EU CT No: 2023-505082-91-00
Phase III, open label, single-arm , non-controlled, in preparation
Landiolol
LANDI-SEP is a Phase IV study in patients with septic shock, to control the heart rate of the patients with a short-acting beta-blocker. The study is currently being conducted in Austria, Germany, Czech Republic, Italy, Lithuania, Estonia, Poland, Hungary and Slovenia.
Study name LANDI-SEP
Indication Septic shock and persistent tachycardia
The LANDI-PED study is investigating the efficacy and safety of Landiolol in children. This is very important and challenging because of the special characteristics of these young and often critically ill patients.
Study name LANDI-PED; EudraCT No. 2015-001129-17
Indication Supraventricular Tachycardia in pediatric patients
Read more clinicaltrialsregister.eu
Effectiveness and safety of AOP Landiolol in controlling supraventricular tachycardia in pediatric patients (LANDI-PED)